Why the study?
Does the angiotensin-converting enzyme inhibitor SQ 14,225 alter hemodynamics and renal vascular function in anesthetized dogs?
Does the angiotensin-converting enzyme inhibitor SQ 14,225 alter hemodynamics and renal vascular function in anesthetized dogs?
The ACE inhibitor SQ 14,225 effectively lowers arterial pressure and increases renal blood flow in a canine model, likely through the inhibition of endogenous angiotensin II production.
ACE inhibition alters canine hemodynamics; hypothesis-generating and leaves open translation to human cardiovascular disease.
The hemodynamic and renal vascular effects of SQ 14,225, a new angiotensin-converting enzyme inhibitor, were studied in mongrel dogs under pentobarbital anesthesia. A dose-related inhibition of the pressor and renal vasoconstrictor effects of AI, but not of AII, were seen after SQ 14,225. After administration of SQ 14,225 (310 μg/kg iv) a moderate decrease in arterial pressure and increase in renal blood flow were observed. It is proposed that the hypotension and renal vasodilation seen after SQ 14,225 could be due to loss of endogenous AII; however, an enhancement of endogenously produced bradykinin cannot be excluded.
No takes yet. Share an insight, caveat, or question.
Murthy et al. (1978) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: